{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:29:07Z","timestamp":1794047347444,"version":"4.8.0"},"reference-count":32,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"3","license":[{"start":{"date-parts":[[2020,2,20]],"date-time":"2020-02-20T00:00:00Z","timestamp":1582156800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/legalcode"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"abstract":"<jats:p>Dickkopf-1 (DKK1), broadly expressed by tumor cells from human multiple myeloma (MM) and other cancers but absent from most normal tissues, may be an ideal target for immunotherapy. Our previous studies have shown that DKK1 (peptide)-specific cytotoxic T lymphocytes can effectively lyse primary MM cells in vitro. To develop DKK1-based vaccines that can be easily and inexpensively made and used by all patients, we identified a DKK1 long peptide (LP), DKK13-76-LP, that contains 74 amino acids and epitopes that can potentially bind to all major MHC class I and II molecules. Using HLA-A*0201- and HLA-DR*4-transgenic mouse models, we found that DKK1-specific CD4+ and CD8+ T cell responses, detected by DKK1 short peptide (P20 and P66v)-HLA-A*0201 tetramer staining and cytotoxic assay for CD8+ T cells or by CSFE dilution and IFN-a; secretion for CD4+ T cells respectively, can be induced in vivo by immunizing mice with the DKK13-76-LP. In addition, DKK13-76-LP also induced anti-DKK1 humoral immunity in the transgenic mice and the DKK1 antibodies were functional. Finally, DKK13-76-LP stimulated human blood T cells ex vivo to generate DKK1-specific CD4+ and CD8+ T cell responses from eight out of ten MM patients with different MHC backgrounds.  The generated DKK1-specific CD8+ cells efficiently lysed autologous MM cells from these patients. Thus, these results confirm the immunogenicity of the DKK13-76-LP in eliciting DKK1-specific CD4+ and CD8+ T cell responses in vitro and in vivo, and suggest that the DKK13-76-LP can be used for immunotherapy of MM and other cancers.<\/jats:p>","DOI":"10.3324\/haematol.2019.236836","type":"journal-article","created":{"date-parts":[[2020,2,20]],"date-time":"2020-02-20T11:15:33Z","timestamp":1582197333000},"page":"838-846","source":"Crossref","is-referenced-by-count":2,"title":["Identification of an immunogenic DKK1 long peptide for immunotherapy of human multiple myeloma"],"prefix":"10.3324","volume":"106","author":[{"family":"Rong Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Chengyun Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Qiang Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Enguang Bi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Maojie Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Jian Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Weijun Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Qing Yi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Jianfei Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2020,2,20]]},"reference":[{"key":"22678","doi-asserted-by":"crossref","unstructured":"Tian E, Zhan F, Walker R. The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med. 2003; 349(26):2483-2494.","DOI":"10.1056\/NEJMoa030847"},{"key":"22679","doi-asserted-by":"crossref","unstructured":"Politou MC, Heath DJ, Rahemtulla A. Serum concentrations of Dickkopf-1 protein are increased in patients with multiple myeloma and reduced after autologous stem cell transplantation. Int J Cancer. 2006; 119(7):1728-1731.","DOI":"10.1002\/ijc.22033"},{"key":"22680","doi-asserted-by":"crossref","unstructured":"Kohn MJ, Kaneko KJ, DePamphilis ML. DkkL1 (Soggy), a Dickkopf family member, localizes to the acrosome during mammalian spermatogenesis. Mol Reprod Dev. 2005; 71(4):516-522.","DOI":"10.1002\/mrd.20314"},{"key":"22681","doi-asserted-by":"crossref","unstructured":"Hall CL, Bafico A, Dai J, Aaronson SA, Keller ET. Prostate cancer cells promote osteoblastic bone metastases through Wnts. Cancer Res. 2005; 65(17):7554-7560.","DOI":"10.1158\/0008-5472.CAN-05-1317"},{"key":"22682","doi-asserted-by":"crossref","unstructured":"Qian J, Zheng Y, Zheng C. Active vaccination with Dickkopf-1 induces protective and therapeutic antitumor immunity in murine multiple myeloma. Blood. 2012; 119(1):161-169.","DOI":"10.1182\/blood-2011-07-368472"},{"key":"22683","doi-asserted-by":"crossref","unstructured":"Zwaveling S, Ferreira Mota SC, Nouta J. Established human papillomavirus type 16-expressing tumors are effectively eradicated following vaccination with long peptides. J Immunol. 2002; 169(1):350-358.","DOI":"10.4049\/jimmunol.169.1.350"},{"key":"22684","doi-asserted-by":"crossref","unstructured":"Vambutas A, DeVoti J, Nouri M. Therapeutic vaccination with papillomavirus E6 and E7 long peptides results in the control of both established virus-induced lesions and latently infected sites in a preclinical cottontail rabbit papillomavirus model. Vaccine. 2005; 23(45):5271-5280.","DOI":"10.1016\/j.vaccine.2005.04.049"},{"key":"22685","doi-asserted-by":"crossref","unstructured":"Disis ML, Wallace DR, Gooley TA. Concurrent trastuzumab and HER2\/neuspecific vaccination in patients with metastatic breast cancer. J Clin Oncol. 2009; 27(28):4685-4692.","DOI":"10.1200\/JCO.2008.20.6789"},{"key":"22686","doi-asserted-by":"crossref","unstructured":"Brunsvig PF, Kyte JA, Kersten C. Telomerase peptide vaccination in NSCLC: a phase II trial in stage III patients vaccinated after chemoradiotherapy and an 8-year update on a phase I\/II trial. Clin Cancer Res. 2011; 17(21):6847-6857.","DOI":"10.1158\/1078-0432.CCR-11-1385"},{"key":"22687","doi-asserted-by":"crossref","unstructured":"Melief CJ, van der Burg SH. Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines. Nat Rev Cancer. 2008; 8(5):351-360.","DOI":"10.1038\/nrc2373"},{"key":"22688","doi-asserted-by":"crossref","unstructured":"Qian J, Wang S, Yang J. Targeting heat shock proteins for immunotherapy in multiple myeloma: generation of myeloma-specific CTLs using dendritic cells pulsed with tumor-derived gp96. Clin Cancer Res. 2005; 11(24 Pt 1):8808-8815.","DOI":"10.1158\/1078-0432.CCR-05-1553"},{"key":"22689","doi-asserted-by":"crossref","unstructured":"Yi Q, Bergenbrant S, Osterborg A. Tcell stimulation induced by idiotypes on monoclonal immunoglobulins in patients with monoclonal gammopathies. Scand J Immunol. 1993; 38(6):529-534.","DOI":"10.1111\/j.1365-3083.1993.tb03236.x"},{"key":"22690","doi-asserted-by":"crossref","unstructured":"Dabadghao S, Bergenbrant S, Anton D, He W, Holm G, Yi Q. Anti-idiotypic T-cell activation in multiple myeloma induced by Mcomponent fragments presented by dendritic cells. Br J Haematol. 1998; 100(4):647-654.","DOI":"10.1046\/j.1365-2141.1998.00633.x"},{"key":"22691","doi-asserted-by":"crossref","unstructured":"Kim Y, Ponomarenko J, Zhu Z. Immune epitope database analysis resource. Nucleic Acids Res. 2012; 40(Web Server issue):W525-530.","DOI":"10.1093\/nar\/gks438"},{"key":"22692","doi-asserted-by":"crossref","unstructured":"Romani N, Reider D, Heuer M. Generation of mature dendritic cells from human blood. An improved method with special regard to clinical applicability. J Immunol Methods. 1996; 196(2):137-151.","DOI":"10.1016\/0022-1759(96)00078-6"},{"key":"22693","doi-asserted-by":"crossref","unstructured":"Lutz MB, Kukutsch N, Ogilvie AL. An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow. J Immunol Methods. 1999; 223(1):77-92.","DOI":"10.1016\/S0022-1759(98)00204-X"},{"key":"22694","doi-asserted-by":"crossref","unstructured":"Alexander J, Oseroff C, Dahlberg C. A decaepitope polypeptide primes for multiple CD8+ IFN-gamma and Th lymphocyte responses: evaluation of multiepitope polypeptides as a mode for vaccine delivery. J Immunol. 2002; 168(12):6189-6198.","DOI":"10.4049\/jimmunol.168.12.6189"},{"key":"22695","doi-asserted-by":"crossref","unstructured":"Tangri S, Ishioka GY, Huang X. Structural features of peptide analogs of human histocompatibility leukocyte antigen class I epitopes that are more potent and immunogenic than wild-type peptide. J Exp Med. 2001; 194(6):833-846.","DOI":"10.1084\/jem.194.6.833"},{"key":"22696","doi-asserted-by":"crossref","unstructured":"Qian J, Xie J, Hong S. Dickkopf-1 (DKK1) is a widely expressed and potent tumor-associated antigen in multiple myeloma. Blood. 2007; 110(5):1587-1594.","DOI":"10.1182\/blood-2007-03-082529"},{"key":"22697","doi-asserted-by":"crossref","unstructured":"Yaccoby S, Ling W, Zhan F, Walker R, Barlogie B, Shaughnessy JD. Antibodybased inhibition of DKK1 suppresses tumorinduced bone resorption and multiple myeloma growth in vivo. Blood. 2007; 109(5):2106-2111.","DOI":"10.1182\/blood-2006-09-047712"},{"key":"22698","doi-asserted-by":"crossref","unstructured":"Corbiere V, Chapiro J, Stroobant V. Antigen spreading contributes to MAGE vaccination-induced regression of melanoma metastases. Cancer Res. 2011; 71(4):1253-1262.","DOI":"10.1158\/0008-5472.CAN-10-2693"},{"key":"22699","doi-asserted-by":"crossref","unstructured":"Ribas A, Timmerman JM, Butterfield LH, Economou JS. Determinant spreading and tumor responses after peptide-based cancer immunotherapy. Trends Immunol. 2003; 24(2):58-61.","DOI":"10.1016\/S1471-4906(02)00029-7"},{"key":"22700","doi-asserted-by":"crossref","unstructured":"Castellino F, Germain RN. Cooperation between CD4+ and CD8+ T cells: when, where, and how. Annu Rev Immunol. 2006; 24:519-540.","DOI":"10.1146\/annurev.immunol.23.021704.115825"},{"key":"22701","doi-asserted-by":"crossref","unstructured":"Aarntzen EH, De Vries IJ, Lesterhuis WJ. Targeting CD4(+) T-helper cells improves the induction of antitumor responses in dendritic cell-based vaccination. Cancer Res. 2013; 73(1):19-29.","DOI":"10.1158\/0008-5472.CAN-12-1127"},{"key":"22702","doi-asserted-by":"crossref","unstructured":"Weide B, Zelba H, Derhovanessian E. Functional T cells targeting NY-ESO-1 or Melan-A are predictive for survival of patients with distant melanoma metastasis. J Clin Oncol. 2012; 30(15):1835-1841.","DOI":"10.1200\/JCO.2011.40.2271"},{"key":"22703","doi-asserted-by":"crossref","unstructured":"Godet Y, Fabre E, Dosset M. Analysis of spontaneous tumor-specific CD4 T-cell immunity in lung cancer using promiscuous HLA-DR telomerase-derived epitopes: potential synergistic effect with chemotherapy response. Clin Cancer Res. 2012; 18(10):2943-2953.","DOI":"10.1158\/1078-0432.CCR-11-3185"},{"key":"22704","doi-asserted-by":"crossref","unstructured":"Kyte JA, Gaudernack G, Dueland S, Trachsel S, Julsrud L, Aamdal S. Telomerase peptide vaccination combined with temozolomide: a clinical trial in stage IV melanoma patients. Clin Cancer Res. 2011; 17(13):4568-4580.","DOI":"10.1158\/1078-0432.CCR-11-0184"},{"key":"22705","doi-asserted-by":"crossref","unstructured":"Kantoff PW, Higano CS, Shore ND. Sipuleucel-T immunotherapy for castrationresistant prostate cancer. N Engl J Med. 2010; 363(5):411-422.","DOI":"10.1056\/NEJMoa1001294"},{"key":"22706","doi-asserted-by":"crossref","unstructured":"Terpos E, Heath DJ, Rahemtulla A. Bortezomib reduces serum dickkopf-1 and receptor activator of nuclear factor-kappaB ligand concentrations and normalises indices of bone remodelling in patients with relapsed multiple myeloma. Br J Haematol. 2006; 135(5):688-692.","DOI":"10.1111\/j.1365-2141.2006.06356.x"},{"key":"22707","doi-asserted-by":"crossref","unstructured":"Terpos E, Kastritis E, Roussou M. The combination of bortezomib, melphalan, dexamethasone and intermittent thalidomide is an effective regimen for relapsed\/refractory myeloma and is associated with improvement of abnormal bone metabolism and angiogenesis. Leukemia. 2008; 22(12):2247-2256.","DOI":"10.1038\/leu.2008.235"},{"key":"22708","unstructured":"Ding ZC, Zhou G. Cytotoxic chemotherapy and CD4+ effector T cells: an emerging alliance for durable antitumor effects. Clin Dev Immunol. 2012; 2012:890178."},{"key":"22709","doi-asserted-by":"crossref","unstructured":"Walter S, Weinschenk T, Stenzl A. Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival. Nat Med. 2012; 18(8):1254-1261.","DOI":"10.1038\/nm.2883"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/9663\/70610","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/9663\/70611","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/9663\/70610","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T09:56:13Z","timestamp":1794045373000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/9663"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,20]]},"references-count":32,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2021,3,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2019.236836","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2,20]]}}}